Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.53 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5013604 | 0.98 | ALDH1A1 (0.69) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL28694330 | 0.94 | ALDH1A1 (0.64) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL30754005 | 0.87 | HRH3 (0.62) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL5096186 | 0.86 | ALDH1A1 (0.55) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL63778 | 0.86 | ALDH1A1 (0.73) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL30289763 | 0.85 | UBE2T (0.71) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL29475033 | 0.85 | UBE2T (0.71) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL209882 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL31283651 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDPOLBKDM4EALOX15 | |
| SCHEMBL2974981 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDPOLBKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | claimed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1846424-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| CN-115724847-A | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2023-03-03 | — | — | CN | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ALDH1A1 1065/4885HPGD 2089/4885POLB 1346/4885 |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | ALDH1A1 3902/4885HPGD 3103/4885POLB 836/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | ALDH1A1 1375/4885HPGD 4419/4885POLB 2830/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | ALDH1A1 1433/4885HPGD 253/4885POLB 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.